EC ever use among women of reproductive age: 4.9% (DHS 2007)
EC knowledge among women of reproductive age: 48.5% (DHS 2007)
Contraceptive Use: 68.5% (DHS 2007, ever use of a modern method among women of reproductive age)
Registered LNG-EC products:
- Escapelle* - Available only with prescription
- Escapelle 1.5* - Available only with prescription
- Postinor* - Available only with prescription
Registered UPA-EC products:
- Dvella* - Available only with prescription
Registered Mifepristone-EC Products:
- Gynepriston* - Available only with prescription
Products marked with * have been approved by a stringent regulatory authority, such as the WHO Prequalification Programme, the US Food and Drug Administration, the European Medicines Agency, or other.
Where at least one type of ECP is available: Public sector clinics, Pharmacies
Age restrictions for accessing ECPs: No data available
Legal/regulatory documents in which EC is included: Essential Medicines List
Other relevant information: A product containing ulipristal acetate has been registered but is not yet on the market.
In Ukraine, the lowest cadre of health workers allowed to sell/dispense ECPs in the public sector is doctors. The lowest cadre of health workers allowed to sell/dispense ECPs in the private sector is doctors. (Data as of 2013.) (USAID/DELIVER, Contraceptive Security Indicators, 2013)
In 2013, EC was procured by the government (JSI/Deliver data).